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Abstract As a pharmacological approach to potentially im- 
prove gene transfer efficiency into skeletal muscle cells, 
glucocorticoids were shown here to allow efficient transfection 
of cultured and mouse human myoblasts, human pulmonary A549 
cells, but not dog myoblasts, independently of the transfection 
protocol, the reporter gene and the transcription promoter 
employed. Transduction with adenovirus was also increased by 
dexamethasone. Pretreatment of cells 48 h prior to transfection 
was most effective and was shown to be concentration-dependent. 
This effect is mediated by binding to the glucocorticoid receptor, 
but not by glucocorticoid responsive elements present in the 
vectors. The acute dexamethasone ffect could be due to 
increased plasmid entry into the cells as suggested by Southern 
blot, whereas the sustained increase of luciferase activity in 
dexamethasone-treated cultures may be related to intracellular 
mechanisms following cell entry. In mice in vivo, a similar 
increase of luciferase activity upon glucocorticoid treatment was 
found. 
© 1999 Federation of European Biochemical Societies. 
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1. Introduction 
The level of gene transfection efficiency is currently too low 
to envisage gene therapy for disorders affecting muscles, e.g. 
Duchenne muscular dystrophy (DMD), for which it is neces- 
sary to introduce the wild type dystrophin gene into a mini- 
mum of 20% of the myofibers [1]. To obtain functional cor- 
rection of the muscles, different methods of gene transfer are 
being developed [2]. This includes naked DNA, synthetic vec- 
tors, recombinant viruses [3-6] or engineered precursor cell 
grafts [1,7,8]. Besides vector design, it is also necessary to 
increase transfection or transduction efficiencies [9] to allow 
clinical development. 
Human skeletal muscle myoblasts are extremely difficult to 
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transfect in vitro by either calcium phosphate precipitation or 
lipid-complexed plasmids. To our knowledge no report of 
efficient in vitro transfection of human myoblasts has been 
published. In contrast, human myoblast ransduction with 
viral vectors is more effective [10-12]. Cultured human myo- 
blasts may serve as a valuable model to study pharmacolog- 
ical approaches for improving ene transfer efficiency. 
Glucocorticoid hormones have different physiological func- 
tions, including effects on metabolism and the immune system. 
They are widely used clinically as immunosuppressive anti- 
inflammatory agents. The biological effects of glucocorticoids 
are generally thought o be mediated by an intracellular (cy- 
toplasmic) receptor protein, the glucocorticoid receptor (GR). 
Upon steroid binding, the GR dissociates from its protein 
complex, enters the nucleus, dimerizes and binds to specific 
DNA sequences called glucocorticoid responsive lements 
(GRE), which participate positively or negatively in gene reg- 
ulation [13,14]. Glucocorticoids mediate their effects by influ- 
encing gene expression and protein synthesis at essentially all 
known levels of regulation. Due to their lipophilicity, gluco- 
corticoids may also modify membrane fluidity [15]. The vari- 
ous known effects of glucocorticoids (gene regulation, alter- 
ation of membrane fluidity, reduction of inflammation and 
immunity) may thus represent a successful way to improve 
gene transfer to cells ex vivo and in vivo. Those properties 
combined with the known trophic effects of glucocorticoids on 
skeletal muscle cells of various species (see for example 
[16,17]) and the clinical benefit provided by glucocorticoids 
in DMD [18,19] led us to investigate their potential in gene 
transfer into skeletal muscle cells. 
2. Materials and methods 
2.1. Materials 
Dexamethasone, cortisol, indomethacin, nordihydroguaiaretic acid, 
quinacrine, and ionomycin were purchased from Sigma Chemicals (St. 
Louis, MO, USA); RU38486 was provided by Bruno Dumas (Roussel 
UCLAF, Romainville, France). c~-Methylprednisolone (Solumedrol) 
was from Upjohn (Paris, France). Concentrations u ed were deter- 
mined according to previously published ata on biological effects 
on cell cultures including human myoblasts [16,17]. 
2.2. Cell cultures 
Primary satellite cells' (myoblasts). Muscle cultures were established 
from satellite cells of portions of muscle biopsies: (a) control patients 
X and Y: spinal muscle biopsies of two 15-year-old girls who had 
undergone orthopedic surgery, (b) spinal muscle biopsy of a 14-year- 
old male diagnosed with DMD, (c) mouse C57BL/10 quadriceps 
muscle, and (d) dystrophic Golden retriever dog extensor digitorum 
longus muscle. Except for mouse muscles that were subjected to en- 
zymatic digestion, cells were harvested from explant cultures and 
grown in Ham's F14 medium (Life Technologies) upplemented 
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with 10% fetal calf serum (Hyclone, Logan, UT, USA), 10 [ag/ml 
insulin, 10 ng/ml epidermal growth factor (both from Sigma), 10 ng/ 
ml basic fibroblast growth factor (PeproTech, Rocky Hill, NJ, USA), 
2 mM glutamine (bioM6rieux, Marcy l'Etoile, France) and 40 pg/ml 
gentamicin (Schering-Plough, Kenilworth, N J, USA) [20,21]. Experi- 
ments were performed on myoblasts obtained after a maximum of 12 
passages and seeded (104 cells/cm 2) on 0.1% gelatin-coated supports. 
Culture supports were either 96, 24 or 6 microwell plates (Falcon, 
Becton Dickinson, Franklin Lakes, NJ, USA), depending on the ex- 
perimental design. The muscle phenotype of the primary cells was 
determined by immunocytochemistry tbr desmin, dystrophin (NCL 
anti-dystrophin monoclonal antibodies, Novocastra) and their ability 
to fuse to form myotubes. Proportions of myoblasts in the cultures 
used for our experiments were between 70 and 90%. 
A549 cells (ATCC CCL 185, epithelial cells" derived j~'om a human 
pulmona O, earcinoma) were cultured in (DMEM) containing 10% fetal 
calf serum (Life Technologies, Cergy-Pontoise, France). 
2.3. Vectors and gene transfer procedures 
2.3.1. Plasmids. The plasmids used for the transfection experi- 
ments were: pTGlI033, an Escheriehia coli plasmid, based on the 
ColE1 origin of replication. It carries an expression cassette ncoding 
the firefly luciferase gene [22] with the mouse HMGCR intron [23] and 
driven by the human cytomegalovirus IEI promoter (from pCEP4, 
InVitrogen, Abingdon, UK). pTGl1034 has the same backbone as 
pTG11033, and carries a lacZ gene with a nuclear localization signal 
instead of the luciferase gene. pTGI 1174 is a derivative of pTG11033 
resulting from the replacement of the CMV IE1 promoter by the RSV 
promoter (from pREP4, lnVitrogen), pTG11056 contains the same 
luciferase expression cassette as pTGl1033 and is devoid of any 
GRE sequence, pTG11096 is a derivative of pTG11056 with the U3 
domain from the LTR of the Friend murine leukemia virus (FB29 
strain [24]) and a GRE sequence about 600 bp upstream to the poly- 
adenylation signal of the luciferase expression cassette, pCHll0N, 
generously provided by Prof. Pierre Chambon (IGBMC, Strasbourg, 
France), derives from pCHll0 [25]; it carries the lacZ gene with a 
nuclear localization signal and under the control of the early promoter 
of SV40. Plasmids were amplified in E. coli strain MC1061 and puri- 
fied by double CsC1 gradient centrifugation after alkaline lysis accord- 
ing to standard techniques [26]. Purified plasmid DNA was concen- 
trated to 1 mg/ml in 10 mM Tris, 1 mM EDTA, pH 7.5. 
Calcium phosphate transfections were performed according to the 
standard protocol [27] on either adherent (0.5, 2 or 1 ~tg plasmid 
DNA/well of 96 or 24 well plates or 8 well Lab-Tek tissue culture 
chambers (Nunc, Naperville, IL, USA) or suspended cells (obtained 
by trypsinization, mixed with plasmid DNA and then immediately 
allowed to seed in the culture plates [28]). 
For transfections with DNA-lipid complexes, Lipofectin reagent 
(Life Technologies) was used according to the manufacturer's ecom- 
mendations and at a weight/weight ratio of 4 lipofectin/l DNA, di- 
luted in PBS and added (50 ~tl/0.5 ~g DNA/well) to cultures in 96 well 
plates. 
2.3.2. Adenovirus. Replication-defective virus was obtained as de- 
scribed [29,30]. It carries the firefly luciferase gene under the control of 
the Ad2 MLP promoter. Viral vector preparations (MOI ranging 
from 10 to 200 IU) were added to the cells cultured in 24 well plates 
in 100 ~tl PBS buffer. After 30 min incubation at 37°C in air plus 5% 
CO2, 1 ml of culture medium was added in each well. 
2.3.3. In vivo gene transJer. The luciferase plasmid (pTG11033 in 
TE buffer) was injected i.m. (25 ~g/25 ~tl in both right and left tibialis 
anterior muscles) in 5-10 week old C57BL/10 mice, 4~6 mice per 
condition (total: up to 10 samples per condition). At various time 
points (1-8 weeks) after injection of the vectors, mice were killed 
and tibialis anterior muscles were retrieved and frozen. Luciferase 
activity was determined on the frozen muscle extracts. For glucocorti- 
coid treatment, in order to avoid any interference, mice were admin- 
istered i.m. on a daily basis in a different muscle (namely into the right 
and left quadriceps muscle alternately) than the plasmid-injected 
muscles. Treatment was 1 mg/kg (a commonly used dose) of c~-meth- 
ylprednisolone (Solumedrol), starting 2 days before plasmid injection, 
on a daily basis until 10 days after injection and 5 times per week 
through the 46 following days. Control animals were non-glucocorti- 
coid-injected mice. 
When performed, anesthesia was obtained after an intraperitoneal 
100 ~tl injection of a mixture of 1 ml lmalghne 1000 (Rh6ne-M6rieux, 
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Lyon, France), 0.5 ml Ronpun 2% (Bayer Pharma, Puteaux, France) 
and 5.2 ml NaC1 0.9°/,,. 
2.4. Parameters analyzed 
Unless specified otherwise, cells were analyzed 48 h after transfec- 
tion. 
2.4.1. Reporter expression. Luciferase was extracted from cell 
layers or frozen muscle samples according to Manthorpe t al. [31]. 
Samples were analyzed using the Luciferase Assay System (Promega) 
in 96 well microtiter plates in a Berthold LB96P luminometer. For 13- 
galactosidase (~-Gal) staining, cells were fixed with 2% formaldehyde/ 
0.2% glutaraldehyde in PBS for 10 min at 4°C, and stained in a 
standard manner [32]. 
2.4.2. Detection of pTGll033 plusmid by Southern blot. DNA was 
extracted from the cultures and digested with HindIII (Life Technol- 
ogies) according to manufacturer's specifications. Samples of 1 ~g 
genomic DNA were loaded onto a 1% agarose gel. Various concen- 
trations of plasmid were analyzed in parallel for quantitative estima- 
tion. After migration, denaturation and transfer overnight on Hy- 
bond-N + membrane (Amersham), hybridization was performed with 
a BamH1-HindIII 700 bp fragment complementary to the luciferase 
expression cassette and radioactively labelled using the Megaprime 
DNA labelling system for aatoradiography. 
2.4.3. Protein concentration. Protein concentration was deter- 
mined with the BCA protein assay kit (Pierce, Rockford, IL) using 
bovine serum albumin as standard. 
2.4.4. Statistical analyses. Unpaired Student's t-test was used and 
the P value given. 
3. Results and discussion 
3.1. Dexamethasone enhances gene transfer & a 
concentration- and time-dependent fashion 
Human myoblasts were cultured in the presence or absence 
of 10 6 M dexamethasone. Cells were transfected by the cal- 
cium phosphate transfection method with the luciferase re- 
porter gene plasmid pTGl1033,  harvested 48 h later, and 
luciferase activity was determined. We observed that pretreat- 
ment of cell cultures for 24-48 h, and continuous presence of 
dexamethasone until cell harvesting, resulted in a significant 
increase in expression levels of the reporter gene (Fig. 1). 
When cells were transfected in suspension, the overall trans- 
gene expression and glucocorticoid enhancement were even 
greater (about 30-fold) than for adherent cells (two experi- 
ments, data not shown). Glucocorticoid treatment initiated 
at the time of (to) or 1, 4, or 24 h after transfection did not 
significantly increase reporter gene expression (Fig. 1A,B). 
The effect of dexamethasone on human myoblast ransfection 
was concentrat ion-dependent (no enhancement below 10 -9 M, 
then increasing with a plateau at 10 -7 M) (Fig. 1C). When the 
dexamethasone treatment was discontinued in pretreated cul- 
tures at the time of transfection, expression levels were lower 
than in continuously treated cultures (Fig. 1B). Transfection 
of human myoblasts with plasmids carrying a nls-lacZ expres- 
sion cassette replacing the luciferase cassette on the same 
(pTGl1034) or on a different plasmid backbone (pCHl l0N)  
showed more [3-Gal-positive cells after dexamethasone treat- 
ment. While only very rare blue cells were seen 48 h following 
transfection (even of suspended cells), around 30% 13-Gal-ex- 
pressing myoblasts were obtained upon dexamethasone treat- 
ment (and after transfection of the resuspended human myo- 
blasts). This suggests either that more cells are being 
transfected upon treatment, or a stimulation of expression 
above the detection threshold which would highlight more 
cells. 
The transfection of both healthy (two donors) and DMD 
(one donor) human myoblasts was enhanced equally by dexa- 
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Fig. 1. Dexamethasone effect is dependent on concentration, onset and duration of treatment. A and B: Time dependence of dexamethasone ef-
fect. Calcium phosphate transfections performed on human myoblast cultures (donor Y). Empty bars: Control (non-dexamethasone-treated) 
transfected cultures. Full black bars: dexamethasone-treated cultures. 48h pretr., 24h pretr.: dexamethasone (1 gM) was added to the culture 
medium 48 h or 24 h prior to transfection and maintained throughout the culture, t0: dexamethasone added to the culture medium along with 
the calcium phosphate precipitated luciferase plasmid (pTGl1033). lh, 4h, 24h: onset of dexamethasone tr atment at 1, 4, or 24 h after trans- 
fection, respectively. Pretr. up to tO: dexamethasone added 48 h before transfection and removed immediately prior to transfection. Luciferase 
activity was determined 48 h after transfection. Bars represent mean + S.E.M. of four values of a particular experiment. The experiment was re- 
peated twice and produced similar results. C: Concentration-response study of dexamethasone; effect on transfection of human (donor X) myo- 
blasts with pTGl1033 (luciferase plasmid). Not shown: cultures treated with ethanol (solvent for dexamethasone) at concentrations 0.01, 
0.1 and 1% (the latter being 10 times in excess) with luciferase activities imilar to non-glucocorticoid-treated cultures. Onset of treatment was 
48 h prior to transfection and the treatment was maintained until cell harvesting (48 h post-transfection). Bars are mean + S.E.M. of six values. 
The experiment was repeated once with similar results. D: Effect on transduction with an adenovirus luciferase vector (MLP promoter). Full 
black bars: dexamethasone (1 ~tM)-treated cultures (48 h pretreatment and maintained until harvesting, 48 h after gene transfer). ND: not de- 
termined. Bars are mean+ S.E.M. of six values. Myoblasts of donor X were used. **P< 0.01; *P< 0.05 as compared to control transfected 
cultures. 
methasone (not shown), which excludes any artefact linked 
to a single cell type or cell clone. Considering the different 
muscles cultured (spinal, extensor digitorum longus, quadri- 
ceps), the dexamethasone effect does not seem to be linked to 
the type of muscle. Variations in amplitude of the glucocorti- 
coid effect may be explained by several factors such as trans- 
fection efficiencies and responsiveness to glucocorticoids of 
primary cultured cells, and experimental conditions. An en- 
hancement effect was also found in mouse primary myoblasts 
(85% increase, not shown), the human pulmonary cell line 
A549 (70% increase, not shown) and the human cell line 
293 (97%+ 27% increase, seven experiments). On the other 
hand, primary dog myoblasts did not respond to the dexa- 
methasone treatment, and VERO and CHO cells displayed only 
a mild (25%) dexamethasone-induced enhancement of transfec- 
tion (data not shown). It remains unclear why some cells 
respond well to glucocorticoids whereas others do not or only 
moderately. Differences in constitutive glucocorticoid receptor 
expression or downstream echanisms may be involved. 
When compared to non-treated cells, at to, only a non-sig- 
nificant increase by 13.0+ 12.9% (six experiments) of total 
protein content and by 10.8+3.8% of the cell number 
(counted after cell dissociation) was observed in dexametha- 
sone-treated cells. At the time of cell harvest, a slight increase 
(29.1 + 12.3%, 10 experiments) of total proteins was observed 
in glucocorticoid-treated cells. Compared to this small in- 
crease in total proteins, the increase in expression levels was 
much higher. Furthermore, dexamethasone-induced increase 
of luciferase expression was also found in mitomycin C-ar- 
rested cells. Mitomycin (5 gM) was added to the culture me- 
dium of dexamethasone-treated c lls or non-glucocorticoid- 
treated cells, 24 h before transfection with luciferase plasmid 
(pTGl1033). Prolonged exposure (48 h) to mitomycin was 
toxic. Cultures were rinsed 4 h after transfection, and mito- 
mycin was then omitted, whereas dexamethasone treatment 
was maintained throughout he experiment. Dexamethasone 
increased luciferase activity 4.4-fold in mitomycin-arrested 
cultures (4.27+0.82X l0 s versus 1.04+0.21× 108 RLU/mg 
proteins, P<0.01)  and 4.8-fold in the same experiment in 
non-arrested cultures (n = 6, P < 0.001) (two experiments per- 
formed). This suggests that the enhanced expression in gluco- 
corticoid-treated cell cultures cannot simply be explained by 
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an increase in cell number subjected to transfection or by 
their higher survival after transfection. Luciferase activity 
was two-fold higher in the non-mitomycin-treated cultures 
as compared to the mitomycin-arrested cultures (P< 0.05), 
which could be explained by the overall toxicity of mitomycin 
and/or the lower transfection capacity of the non-dividing 
cells. 
3.2. The observed effect is specific to glucocorticoids 
The two other glucocorticoids tested, cortisol and c~-meth- 
ylprednisolone (both at 10 -6 M and with 48 h pretreatment) 
enhanced luciferase activity as did dexamethasone. Their re- 
spective induced increases of transgene xpression were 3.3, 
3.3 and 2.4 with P values < 0.001, 0.001 and 0.05 respectively 
(n -- 4 wells). Other steroids (progesterone and testosterone) or
the ]3-adrenergic agonist anabolic clenbuterol did not influence 
transgene xpression (not shown), whereas the enhancing ef- 
fect was found constantly throughout he 20 experiments in- 
volving glucocorticoids. 
3.3. The effect was not linked to the protocol of  transfection nor 
to the promoter sequences or reporter gene 
The efficiency of lipofection with our luciferase plasmid 
pTGl1033 complexed with lipofectin was also increased by 
dexamethasone; luciferase activity in transfected cultures 
was respectively 4.1 + 1.7 × 10 7 RLU/mg proteins and 
18.6 + 5.2× l07 RLU/mg proteins (P< 0.001, n = 6 wells). 
Transduction with an adenovirus encoding the luciferase 
gene under control of the MLP promoter was also enhanced 
by dexamethasone (Fig. 1D). The lack of influence of the 
nature of the promoter was further demonstrated by the sim- 
ilar dexamethasone-induced nhancements of transfection 
with plasmid pTG11174 containing the RSV promoter instead 
of the CMV promoter (but otherwise identical to our lucifer- 
ase plasmid pTGl1033) with respective luciferase activities 
being 1.2_+0.5× 107 and 11.4_+3.5x 107 RLU/mg proteins 
(P<0.001,  n=6 wells), as well as with the ~-Gal plasmid 
which contains the SV40 early promoter. 
3.4. Binding of  glucocorticoid to the cytoplasmic receptor and 
the role of  GRE sequences 
RU38486, the steroid receptor antagonist, was added 
(10 gM) to the culture medium 1 h before dexamethasone 
(1 gM), that is 48 h prior to transfection. Both were main- 
tained until cell harvesting (48 h after transfection). RU38486 
abolished the dexamethasone effect: there was no signifi- 
cant difference in luciferase activity between dexametha- 
sone+RU38486-treated cultures (9.8 +2.0× 10 s RLU/mg 
proteins) and cultures treated with RU38486 alone 
(6.7_ + 1.0×108 RLU/mg proteins), whereas in the same ex- 
periment 54.4+ 3.4X 108 RLU/mg proteins where found in 
the dexamethasone-treated cultures and 16.5 + 3.6× 108 
RLU/mg proteins in control untreated cultures (P<0.01 ;  
n = 6 wells). This shows that binding of the glucocorticoid to 
its receptor is necessary. The slight decrease in luciferase ac- 
tivity found in RU38486-treated cultures as compared to con- 
trol could be due to inhibition of cortisol present in low 
amounts (10 8-10-9) in the fetal bovine serum used in the 
culture medium. 
On the other hand, we found that the presence of the cis- 
regulatory DNA GRE sequences [13] on the plasmid were not 
required for the glucocorticoid effect, since transfection with 
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ing 2 days before transfection and treatment was maintained 
throughout the experiment (up to 14 days after transfection). Lower 
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one experiment. A similar pattern was obtained in a second experi- 
ment. 
a plasmid that did not contain GREs was also increased 
by dexamethasone. Comparisons were performed with two 
isogenic plasmids containing the same promoter plus 
(pTG11096) or minus (pTG11056) GRE sequences. Dexame- 
thasone (48 h pretreatment) stimulation of human myoblast 
transfection was obtained with both plasmids. In this experi- 
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ment (repeated once, with myoblasts of donor X and of donor 
Y), luciferase activities in control cultures transfected with 
pCMV plasmid (pTG 11033), pTG 11096 and pTG 11056 were 
respectively 7.5 + 1.3, 8.2 + 1.2 and 5.8 + 0.6 × 108 RLU/mg 
proteins and were increased respectively 7.0-, 4.5-, and 8.0- 
fold upon dexamethasone (1 gM) treatment (n =6; P values 
all < 0.001). 
This suggests that the enhancement of reporter gene expres- 
sion is not a direct response but rather mediated by cellular 
GRE-responsive gene(s). This interpretation is in contradic- 
tion with, but does not exclude, the possibility stated else- 
where [33] of a plasmid nuclear translocation driven by cyto- 
plasmic glucocorticoid receptor bound to plasmid GREs. The 
effect described here may not occur through a classical GRE- 
mediated mechanism, which has been reported previously in 
other cases (see for example [34]). 
3.5. Intracellular calcium and arachidonie acid cascade are not 
involved in the dexamethasone effect on cell transJection 
The anti-inflammatory effect of glucocorticoids is attributed 
to a significant degree to their suppressive activity on the 
arachidonic ascade at multiple levels [13]. We investigated 
this pathway using different enzyme inhibitors. The molecules 
tested, quinacrine 30 ~tM, nordihydroguaiaretic acid 0.01 laM 
and indomethacin 0.1 ~tM, which inhibit phospholipase A2 (as 
do glucocorticoids [19]), cyclooxygenase and lipoxygenase, 
were without effect on transfection of human myoblasts (the 
test molecules were added to the culture medium 48 h before 
transfection and maintained until cell harvesting 2 days after 
transfection). 
As calcium metabolism ay also mediate glucocorticoid 
effects [13] we investigated methoxyverapamil or the calcium 
ionophore ionomycin (both at 1 ].tM) which either decrease or 
increase intracellular calcium concentration. Both agents had 
no significant influence on the dexamethasone effect on hu- 
man myoblast transfection. Luciferase activities of non- 
treated control, methoxyverapamil, and ionomycin cultures 
were 4.1 + 1.5, 3.7 +0.3 and 1.9 +0.4× 108 RLU/mg proteins 
respectively and 13.7 + 0.8, 17.2 + 1.6 and 4.9 + 0.5 × 108 RLU/ 
mg proteins in their dexamethasone-treated counterparts (P 
values all < 0.01, n -- 6). The lower luciferase activity observed 
in ionomycin-treated cultures could be explained by toxicity 
provoked by the elevated cellular calcium content over the 
4 day duration of the treatment. 
As pretreatment of at least 24 h with glucocorticoids pro- 
duced a maximal effect on cell transfection, one can speculate 
that an accumulation of factor(s) may be necessary, Since the 
effect was not dependent on transfection protocols and since 
adenoviral vectors and plasmids do not use the same penetra- 
tion mechanisms, our observations may reflect at least in part 
an accumulation of the factor(s) inside the cell. Whether this 
accumulation is due to increased transgene xpression, in- 
creased messenger or protein stability remains to be investi- 
gated. This observation also excludes direct short term effects 
of glucocorticoids such as increased membrane fluidity [18] 
(which would enhance vector penetration i to cells), or short 
term effects on vector DNA transcriptional or post-transcrip- 
tional processes. Therefore the most likely mechanism of ac- 
tion might be an indirect one, through the regulation of cel- 
lular (i.e. transcriptional) factors, but with no implication of 
the arachidonic ascade and changes in cytoplasmic alci- 
um. 
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(Anaesth.) or in c~-MPred-treated anesthetized mice (Anaesth.+a- 
MPred). No anaesth. : non-anesthetized mice injected with 
pTGl1033. The injected muscles (right and left tibialis anterior) 
were retrieved 7 days after plasmid injection. Bars are mean_+ 
S.E.M. of eight values. Bars are mean+S.E.M, of 10 values. 
*P < 0.05 as compared to Anaesth.; **P < 0.01 as compared to No 
anaesth. The experiment was repeated four times with similar re- 
sults. 
3.6. Dexamethasone increases' reporter gene expression long 
term 
As shown in Fig. 2A, in the absence of dexamethasone, 
luciferase activity decreased with time (empty squares) (end 
of experiment: 14 days after transfection). This drop was 
not observed in dexamethasone-treated cultures (dexametha- 
sone applied 48 h before transfection and maintained 
throughout the culture, full black squares). As also shown 
above, no difference in luciferase activity was observed 
2 days after transfection i  cultures treated with dexameth- 
asone at to of transfection (full black triangles) as compared 
to non-treated cultures (empty squares); however, at later 
time points, as dexamethasone was maintained in the culture 
medium, luciferase xpression i creased (full black triangles). 
When dexamethasone tr atment was applied 4 h after trans- 
fection, no long-term increase was obtained. When dexa- 
methasone was applied up to to, no increase (short or long 
282 S. Braun et al./FEBS Letters 454 (1999) 277-282 
term) was found (double crosses). Upon dexamethasone 
removal from the culture medium 48 h after transfection 
of glucocorticoid-pretreated cultures, transgene expression 
dropped (full black circles). Differences at 14 days post-trans- 
fection between to dexamethasone-treated cultures and 48 h 
pretreated cultures may have been attenuated over the long 
term or may reflect a maximum of transgene xpression. A
significant expansion in cell number was observed over the 
16 days of this experiment, which would dilute out the ex- 
pression from our non-replicating plasmid, thus leading to 
underestimation f the dexamethasone effect. Therefore, the 
results presented are not being expressed per mg proteins. 
3.7. Effect of  dexamethasone onplasmid entry and maintenance 
into cells 
As shown in Fig. 2B, the amount of transfected plasmid 
was increased approximately 3 times in dexamethasone- 
treated cultures at 4 h post-transfection. Nevertheless, at 
this time point results may have been biased by the plasmid 
DNA which may have been retained on the cellular mem- 
brane. This possibility is, however, unlikely for the further 
time points since untransfected plasmid DNA should be de- 
graded shortly after incubation with the cultures. 
We found that plasmid signal was also increased in dexa- 
methasone-treated cultures 2 days (3.1 times), 7 days (5 times) 
and 14 days (4.6 times) after transfection. The number of 
plasmid copies per culture remained stable between 2 and 14 
days after transfection in both control and dexamethasone- 
treated cultures (two experiments). 
Therefore, two major effects are found: (A) a transient in- 
crease of gene expression of glucocorticoid-pretreated c lls 
through increase of plasmid entry and perhaps through trans- 
gene expression and (B) a long term enhancement of gene 
expression through an action on the level of transgene xpres- 
sion or downstream echanisms. 
3.8. Glucocorticoid increase i.rn. gene transfer in vivo 
C57BL/10 mice were treated with cx-methylprednisolone (1 
mg/kg, i.m. quadriceps - injections) on a daily basis, starting 
2 days before plasmid (pTG11033) injection into right and left 
tibialis anterior. Luciferase activity of each of the whole 
muscles was determined at various time points after plasmid 
injection (which corresponds to the peak time point of trans- 
gene expression, according to our previous experiments, not 
shown). We found that luciferase activity was increased 3 times 
in c~-methylprednisolone-treated animals (Fig. 3A) 7 days 
after injection. Luciferase activity decreased starting 2 weeks 
after injection in both control and c~-methylprednisolone- 
treated mice. We observed that, when mice were anesthetized 
(with an intraperitoneal injection of either xylazine/ketamine 
or pentobarbital) before plasmid injection, transgene (lucifer- 
ase) expression was lowered (by a factor of 4) as shown in Fig. 
3B (only results of xylazine/ketamine-anesthetized mice are 
shown). This phenomenon measured 7 days after plasmid ad- 
ministration was partially reversed ue to the cx-methylpred- 
nisolone effect (Fig. 3B). 
Glucocorticoids may potentially increase in vivo gene trans- 
fer per se, but an indirect effect through different mechanisms 
such as anti-inflammatory [17] and immunosuppressive ac- 
tions cannot be excluded. However, the long term effect was 
not confirmed in vivo. Additional investigations are needed to 
study more precisely both phenomena. The explanation for 
the impairment of gene transfer due to anesthesia carried 
for i.m. plasmid injection also deserves more specific investi- 
gations. It could be related to the lack of muscle contractile 
activity during anesthesia (which lasted about up to 20 min 
after plasmid injection), which could lead to impaired diffu- 
sion of the vector into the muscle tissue or lack of charge 
repulsions between the resting muscle fibers (which are nega- 
tively charged in contrast o contracting muscle fibers) and the 
negatively charged plasmid DNA. 
In conclusion, the present report demonstrates that it is 
possible to pharmacologically enhance gene transfer into skel- 
etal muscle cells. This may lead to important applications in 
ex vivo and direct in vivo delivery approaches of therapeutic 
genes in patients with neuromuscular disorders. 
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